Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

Element Biosciences, Inc.. (3/14/22). "Press Release: Element Launches the AVITI System to Democratize Access to Genomics".

Organisations Organisation Element Biosciences Inc.
  Organisation 2 Agilent Technologies Inc. (NYSE: A)
Products Product AVITI™ sequencing system
  Product 2 DNA sequencing technology
Persons Person He, Molly (Element Biosciences 202001 CEO + Co-Founder)
  Person 2 Enes, Valerie (Seismic Marketing 202110)
     


Introducing AVITI™ - a benchtop DNA sequencer with unprecedented performance, cost, and flexibility.


Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, today announced the commercial launch of the Element AVITI™ System, a benchtop sequencer offering an unrivaled combination of performance, cost, and flexibility. Element’s proprietary Avidity Sequencing™ chemistries enable exceptional accuracy and cost efficiency that is unmatched by other benchtop systems. The AVITI™ System operates two random access flow cells that enable independent run start flexibility of each flow cell, and the AVITI™ operating software features tunable read throughput control for additional run time flexibility.

The launch of the AVITI™ System is the latest in a series of announcements that have highlighted Element’s key partnerships with established and emerging leaders in the NGS Library Prep and Bioinformatics segments, each of whom demonstrates powerful use cases for the AVITI™ System.

These partners include, in alphabetical order:

> Agilent Technologies
> Dovetail Genomics
> Fabric Genomics
> Genoox
> Google DeepVariant
> Jumpcode Genomics
> New England Biolabs (NEB)
> QIAGEN
> Roche
> Sentieon
> 10x Genomics
> Watchmaker Genomics

“With the launch of our AVITI™ System, Element is delivering on its vision to dramatically expand access to high quality, low cost, easy-to-use genomics tools,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “And with the recent Loop Genomics acquisition, we will offer both short and long-read capabilities on a single platform. AVITI™ will bring the ultimate freedom and flexibility for users.”

“In beta testing both the library compatibility and sequencing performance proved to be as straightforward and impressive as we’d hoped. Users will feel very confident with adopting the AVITI™ System in terms of both workflow and data quality,” said Shawn Levy, Senior Vice resident of Applications and Scientific Affairs, Element Biosciences.

“There is often a sacrifice between accuracy, throughput, and costs. With Element’s new benchtop sequencer, researchers will not be forced to make those compromises. They will receive industry-leading quality and cost at a throughput level that more closely matches the needs of most applications,” said John Stuelpnagel, chairman of Element Biosciences.

Element has released seven application and technology notes along with five sequencing datasets for download that cover human whole genome, bacterial whole genome, and RNA-Seq assays using the Element AVITI™ System.

Element is now accepting orders for the AVITI™ System, with shipments expected to begin in Q2 2022.


The Element AVITI™ System

The AVITI™ System consists of a benchtop NGS instrument and associated consumables that feature:

> Proprietary Chemistries: Delivers exceptional sequencing accuracy while dramatically lowering operating costs and eliminating index misassignments due to amplification

> State of the Art Performance: Accuracy and output metrics that enable a comprehensive range of demanding NGS applications

> Random Access Dual Flow Cells: Scalable output and batch control features; equivalent to having two sequencing systems in one

> Simple NGS Library Prep Compatibility: Easy PCR-free workflow that allows you to start immediately with your library prep of choice

> Open Informatics: FASTQ file output without proprietary requirements for analysis


Key Operating Specifications

The Element AVITI™ System is based on a single flow cell and sequencing reagent cartridge design that offers up to 300-cycles and tunable read throughput control for each of two independently operated flow cells. This allows the user complete run control timing and scalability while being unburdened from the order and inventory complexity of multiple kit sizes.

The AVITI™ System’s operating specifications include:

> 2 x 150 paired end read length
> > 90% Q30 at 2x150 read length
> 800M+ paired end reads per flow cell
> 240Gb of data output per flow cell
> 2 random access flow cells for 480Gb combined output
> 13-48 hour run time
> $5-$7 per Gb run cost*
> AVITI™ Instrument Pricing: $289,000

*Range determined by flow cell output, which can exceed 1000M paired-end reads per run


About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more about Element Biosciences here.

Media contact for Element Biosciences: Valerie Enes | valerie@teamseismic.com | (408) 497-8568

   
Record changed: 2024-01-06

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Element Biosciences Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top